Építés alatt – nem éles oldal
Belépés

NCT02964884Fut, nem toboroz2. fázis

Interventions for Reading Disabilities in NF1

Neurobiology and Treatment of Reading Disability in NF1

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. júl. 1.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

Neurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of neurofibromin - a protein important in a signaling pathway that regulates learning and memory. Our previous work (NS49096) demonstrated that school-age children with NF+RD can respond to standard phonologically-based reading tutoring originally developed to treat reading disability in the general population. Combining our work with that by other researchers suggesting that a medication (Lovastatin) may counteract the effects of the deficient neurofibromin, and possibly ameliorate learning disabilities in NF1, the investigator propose to examine the synergistic effects of medication plus reading tutoring.

Állapot (regiszter)
Fut, nem toboroz
Fázis (regiszter)
2. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
120 (tervezett)
Első benyújtás
2016. nov. 9.
Kezdés
2016. nov.
Elsődleges befejezés
2027. jan.
Fő szponzor
Vanderbilt University
NCT-szám
NCT02964884

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó · 2. fázis
  • Tervezett résztvevők: 120
  • 2016. nov. és az elsődleges befejezés (2027. jan.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Kiket keres a vizsgálat

  • This study will be open to all English speakers who meet eligibility criteria regardless of race, gender, minority or socioeconomic status. Inclusion criteria to be met are listed below:
  • Individuals ages 8-20 (all participants)
  • Documented NF-1 (NF patients only)
  • If female, participant is post-menarche (NF patients only)
  • If male, participant has reached Tanner Stage 2 (NF patients only)
  • Participant able to swallow capsule (NF patients only, may be confirmed via swallowability test, described below)
  • Participant's English is sufficient for school (all participants)
  • Participant must either answer "yes" to question A, or answer "yes" to at least 2 items for questions B-D listed below:
  • Has your child ever been diagnosed with a reading disability? B. Did your child have trouble learning how to "sound out" words? C. Have you (parent) ever been concerned about your child's reading ability? D. Did the school or teacher ever express any concerns about your child's reading ability? Swallowability Assessment: We may ask patients to perform a capsule swallowability assessment prior to enrollment. We will ask subjects to attempt to swallow an empty capsule, matching the same size of the Lovastatin 20mg and 40mg capsules to be used in the study, to confirm swallowability. Patients will be provided with up to 2 capsules as needed to successfully perform the swallowability assessment. If the patient is unable to swallow the capsule, enrollment in the study may deferred or declined.
    • A child will be excluded if he/she meets any of the following criteria, which will be determined by initial telephone screening as well as review of medical/developmental history prior to and during testing:
  • Child 7 years of age or less;
  • known uncorrectable visual impairment;
  • documented hearing impairment greater than or equal to a 25 dB loss;
  • medical contraindication to MRI procedures (e.g., metal devices);
  • any psychiatric, behavioral, or developmental disorder that would preclude active participation in in-depth tutoring sessions
  • Pregnant at time of screening.
  • Known conditions which are contraindicated to Lovastatin
    • Hypersensitivity to the medication
    • Uncontrolled Epilepsy
    • Metabolic Syndrome X, High Blood Sugar,
    • Muscle Damage Due to Autoimmunity
    • Stroke caused by Bleeding in the Brain, Loss of Memory,
    • Severely Low Blood Pressure
    • Liver Problems including Abnormal Liver Function Tests
    • Severe Renal Impairment,
    • Serious Muscle Damage that may Lead to Kidney Failure,
    • Recent Operation or significant Injury
    • Muscle Pain or Tenderness with Increase Creatinine Kinase,
    • Habit of Drinking Too Much Alcohol
    • Pregnant or lactating. - Lovastatin is contraindicated during pregnancy and in nursing mothers because it decreases synthesis of cholesterol and other products of the cholesterol biosynthesis pathway that are essential components for fetal development.
    • Children who meet criteria for ADHD, Oppositional Defiant Disorder, adjustment disorder, and/or mild depression will be eligible as long as they are not taking psychotropic medications, with the exception of stimulant medication for ADHD.
    • For pilot participants only:
    • Criteria for inclusion/exclusion for pilot participants is outlined below. Children who meet criteria for ADHD, Oppositional Defiant Disorder, adjustment disorder, and/or mild depression will be eligible as long as they are not taking psychotropic medications, with the exception of stimulant medication for ADHD.
  • Children ages 8-17
  • Participant is a native English speaker
  • Participant must either answer "yes" to question A, or answer "yes" to at least 2 items for questions 2-4 listed below:
  • Has your child ever been diagnosed with a reading disability? B. Did your child have trouble learning how to "sound out" words? C. Have you (parent) ever been concerned about your child's reading ability? D. Did the school or teacher ever express any concerns about your child's reading ability?
    • A child will be excluded if he/she meets any of the following criteria, which will be determined by initial telephone screening as well as review of medical/developmental history prior to and during testing:
  • Children 7 years of age or younger
  • previous diagnosis of Intellectual Disability;
  • known uncorrectable visual impairment;
  • documented hearing impairment greater than or equal to a 25 dB loss;
  • medical contraindication to MRI procedures (e.g., metal devices);
  • known IQ below 70;
  • a pervasive developmental disorder; and
  • any known neurologic pathology, including epilepsy, spina bifida, cerebral palsy, traumatic brain injury, optic gliomas, and brain tumors (other than UBOs).
  • Comorbid severe psychiatric disorders will also be excluded.

Életkor a regiszterben: 8 év – 20 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Vanderbilt UniversityNashvilleEgyesült ÁllamokIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.